loading
Onkure Therapeutics Inc stock is traded at $15.87, with a volume of 4,512. It is down -0.81% in the last 24 hours and down -14.45% over the past month. OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.
See More
Previous Close:
$16.00
Open:
$16.01
24h Volume:
4,512
Relative Volume:
0.15
Market Cap:
$213.43M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-6.09%
1M Performance:
-14.45%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
Value
$15.50
$16.15
1-Week Range:
Value
$14.71
$16.91
52-Week Range:
Value
$14.71
$19.40

Onkure Therapeutics Inc Stock (OKUR) Company Profile

Name
Name
Onkure Therapeutics Inc
Name
Phone
(720) 307-2892
Name
Address
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
OKUR's Discussions on Twitter

Compare OKUR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
OKUR 15.50 213.43M 0 0 0 0.00
VRTX 446.50 115.74B 10.63B -479.80M -1.35B 13.33
REGN 740.51 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.20 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.97 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.50 24.49B 3.30B -501.07M 1.03B 11.54

Onkure Therapeutics Inc Stock (OKUR) Latest News

pulisher
Nov 20, 2024

OnKure Therapeutics Faces Post-Merger Hurdles: Integration Challenges and Talent Competition Threaten Growth - MSN

Nov 20, 2024
pulisher
Nov 14, 2024

OnKure Therapeutics (OKUR) vs. The Competition Head-To-Head Analysis - Defense World

Nov 14, 2024
pulisher
Nov 09, 2024

OnKure Therapeutics' (OKUR) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Nov 09, 2024
pulisher
Nov 07, 2024

OnKure Therapeutics announces accounting firm change - Investing.com India

Nov 07, 2024
pulisher
Nov 07, 2024

Form 424B3 OnKure Therapeutics, - StreetInsider.com

Nov 07, 2024
pulisher
Nov 07, 2024

Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024
pulisher
Nov 05, 2024

OnKure to Present at the Stifel 2024 Healthcare Conference - GlobeNewswire

Nov 05, 2024
pulisher
Nov 01, 2024

OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium - GlobeNewswire

Nov 01, 2024
pulisher
Oct 25, 2024

VTv, OnKure Terminate Cellular Drug Licensing Agreement - MarketWatch

Oct 25, 2024
pulisher
Oct 25, 2024

vTv Therapeutics ends key license agreement with OnKure - Investing.com

Oct 25, 2024
pulisher
Oct 25, 2024

vTv Therapeutics ends key license agreement with OnKure By Investing.com - Investing.com UK

Oct 25, 2024
pulisher
Oct 25, 2024

vTv Therapeutics Faces License Agreement Termination - TipRanks

Oct 25, 2024
pulisher
Oct 24, 2024

OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond (OKUR) - Seeking Alpha

Oct 24, 2024
pulisher
Oct 21, 2024

Q3 Earnings Forecast for OKUR Issued By HC Wainwright - MarketBeat

Oct 21, 2024
pulisher
Oct 19, 2024

Analysts Offer Predictions for OKUR Q1 Earnings - Defense World

Oct 19, 2024
pulisher
Oct 18, 2024

What is HC Wainwright's Estimate for OKUR Q1 Earnings? - MarketBeat

Oct 18, 2024
pulisher
Oct 17, 2024

HC Wainwright Reiterates Buy Rating for OnKure Therapeutics (NASDAQ:OKUR) - MarketBeat

Oct 17, 2024
pulisher
Oct 14, 2024

OnKure Therapeutics (OKUR) Stock Rebounds In Extended Session - Stocks Telegraph

Oct 14, 2024
pulisher
Oct 11, 2024

OnKure started at outperform by Oppenheimer, OKI-219 potential cited - MSN

Oct 11, 2024
pulisher
Oct 11, 2024

OnKure shares initiated with Outperform rating on drug potential - Investing.com India

Oct 11, 2024
pulisher
Oct 10, 2024

Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm - Benzinga

Oct 10, 2024
pulisher
Oct 10, 2024

OnKure shares initiated with Outperform rating on drug potential By Investing.com - Investing.com Canada

Oct 10, 2024
pulisher
Oct 10, 2024

This Builders FirstSource Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Oct 10, 2024
pulisher
Oct 08, 2024

Reneo Pharmaceuticals Completes Merger and Name Change to OnKure Therapeutics, Inc. - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

Newley merged OnKure raises $65 million - The Pharma Letter

Oct 08, 2024
pulisher
Oct 07, 2024

Boulder’s OnKure goes public with merger; key drug trial underway - Boulder Daily Camera

Oct 07, 2024
pulisher
Oct 07, 2024

OnKure and Reneo Pharmaceuticals complete merger - Pharmaceutical Technology

Oct 07, 2024
pulisher
Oct 07, 2024

Galapagos investor gets board seat; OnKure completes merger with Reneo - Endpoints News

Oct 07, 2024
pulisher
Oct 05, 2024

Reneo Pharmaceuticals stockholders approval merger with OnKure - TipRanks

Oct 05, 2024
pulisher
Oct 04, 2024

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million - StockTitan

Oct 04, 2024
pulisher
Oct 04, 2024

Reneo stockholders approve merger with OnKure - MSN

Oct 04, 2024
pulisher
Oct 02, 2024

Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure - GlobeNewswire

Oct 02, 2024
pulisher
Sep 22, 2024

This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy? - AOL

Sep 22, 2024
pulisher
Sep 17, 2024

Here's Why Everyone's Talking About Summit Therapeutics - AOL

Sep 17, 2024
pulisher
Sep 10, 2024

Oppenheimer sees competition risk as Relay Therapeutics stock stumbles on trial results - Investing.com

Sep 10, 2024
pulisher
Aug 13, 2024

Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results - Yahoo Finance

Aug 13, 2024
pulisher
Jul 26, 2024

OnKure hires ex-Pfizer research leader as chief scientific officer - BizWest

Jul 26, 2024
pulisher
Jun 24, 2024

OnKure Therapeutics - The Pharma Letter

Jun 24, 2024
pulisher
Jun 24, 2024

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc.RPHM - PR Newswire

Jun 24, 2024
pulisher
Jun 19, 2024

OnKure Announces the Appointment of Rogan Nunn, J.D., as General Counsel and Secretary - GlobeNewswire

Jun 19, 2024
pulisher
May 28, 2024

Reneo Set to Close After Test Failure - Orange County Business Journal

May 28, 2024
pulisher
May 17, 2024

Public Equity Report: Erasca reboots, Telix plans NASDAQ listing - BioCentury

May 17, 2024
pulisher
May 15, 2024

Wilson Sonsini Advises Reneo Pharmaceuticals on IP Matters Related to OnKure Merger - Wilson Sonsini

May 15, 2024
pulisher
May 14, 2024

Reneo Pharma to merge with OnKure - The Pharma Letter

May 14, 2024
pulisher
May 13, 2024

With first drug trial underway, OnKure inks merger with Reneo Pharma to go public - BizWest

May 13, 2024
pulisher
Apr 16, 2024

Seven biotech companies climbing their way up in Colorado - Labiotech.eu

Apr 16, 2024
pulisher
Jan 08, 2024

HDAC Inhibitor Clinical Trial Pipeline Appears Robust With - GlobeNewswire

Jan 08, 2024
pulisher
Dec 20, 2023

Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission - Fierce Biotech

Dec 20, 2023
pulisher
May 26, 2023

The Week’s 10 Biggest Funding Rounds: Anthropic Generates Another Huge Round, Biotech Has Big Week - Crunchbase News

May 26, 2023
pulisher
May 23, 2023

OnKure Therapeutics Announces $54 Million Series C Financing - GlobeNewswire

May 23, 2023
pulisher
Feb 28, 2023

2023 Destination Startup® drives investment in intermountain west university innovations - University of Colorado Boulder

Feb 28, 2023

Onkure Therapeutics Inc Stock (OKUR) Financials Data

There is no financial data for Onkure Therapeutics Inc (OKUR). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Onkure Therapeutics Inc Stock (OKUR) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Leonard Braden Michael
10% Owner
Sep 24 '24
Buy
1.41
29,600
41,866
3,388,649
Leonard Braden Michael
10% Owner
Sep 17 '24
Buy
1.36
55,300
75,108
3,358,243
Leonard Braden Michael
10% Owner
Sep 18 '24
Buy
1.40
806
1,128
3,359,049
Leonard Braden Michael
10% Owner
Sep 16 '24
Buy
1.37
172,747
236,871
3,302,943
Leonard Braden Michael
10% Owner
Sep 13 '24
Buy
1.31
150,000
196,950
3,130,196
Leonard Braden Michael
10% Owner
Sep 12 '24
Buy
1.40
36,176
50,523
2,980,196
Leonard Braden Michael
10% Owner
Aug 13 '24
Buy
1.39
171,339
238,590
2,843,533
Leonard Braden Michael
10% Owner
Aug 14 '24
Buy
1.41
100,487
142,008
2,944,020
Leonard Braden Michael
10% Owner
May 14 '24
Buy
1.54
414,281
639,578
2,672,194
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):